MTOR and renal cell carcinoma: The last few decades brought tremendous changes to the therapeutic landscape of metastatic RCC, with the development of numerous tyrosine kinase inhibitors (TKIs), mammalian target of rapamycin inhibitors (mTORis), and immune checkpoint inhibitors (ICPIs).